Trial abstract · §3
MMPOWER-2 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in six-minute walk distance | An increase in six-minute walk distance in a crossover design with a small sample | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for SS-31 (elamipretide) from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Injection-site reaction | — | — | The most common adverse effect and dose-limiting in some participants |
| Injection-site erythema and induration | — | — | Frequent with subcutaneous administration |
| Overall systemic tolerability | — | — | Favourable across a substantial clinical programme; this compound has one of the larger controlled safety datasets in this monograph series |
Compound Evidence Institute · CEI-TR-0131/3 · https://compoundevidence.com/trials/mmpower-2/results/ · retrieved 30 July 2026